A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
Non-alcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis · NAFLD · Metabolic Dysfunction-associated Steatotic Liver Disease · Metabolic Dysfunction-associated Steatohepatitis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 85 (final count)
- Started
- Jul 12, 2024
- Main results expected
- Aug 3, 2026
- Fully finished
- Aug 3, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from Baseline in Liver Fat Content (LFC) at Week 28
Measured over: Baseline and 28 weeks
Percentage of Participants Who Experienced an Adverse Event (AE)
Measured over: Up to approximately 36 weeks
Percentage of Participants Discontinuing Study Medication Due to an AE
Measured over: Up to approximately 28 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06465186 · record last updated 2026-09-21 · checked 2026-11-09 15:47 UTC